Dahmani v. SHL Medical AG

CourtDistrict Court, N.D. Illinois
DecidedJune 14, 2024
Docket1:23-cv-04448
StatusUnknown

This text of Dahmani v. SHL Medical AG (Dahmani v. SHL Medical AG) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dahmani v. SHL Medical AG, (N.D. Ill. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS

Pierre A. Dahmani,

Plaintiff, Case No. 23 CV 04448

v. Honorable Nancy L. Maldonado

SHL Medical AG,

Defendant.

MEMORANDUM OPINION AND ORDER

Plaintiff Pierre A. Dahmani initiated this action against Defendant SHL Medical AG (“SHL Medical”) bringing an individual claim for breach of fiduciary duty, a derivative claim for breach of fiduciary duty, and a derivative claim for accounting. (Dkt. 5-1.)1 After timely removing this case to federal court on diversity grounds, SHL Medical filed a motion to dismiss Dahmani’s Complaint. (Dkt. 29.) SHL argues that Dahmani’s Complaint should be dismissed under the forum non conveniens doctrine and, alternatively, for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6). For the reasons stated in this Memorandum Opinion and Order, the Court grants SHL Medical’s motion to dismiss for forum non conveniens. The Court therefore will not address SHL Medical’s separate Rule 12(b)(6) motion. The case is dismissed.

Background2

Plaintiff Pierre A. Dahmani is one of three of the original founding members of the QuiO Corporation (“QuiO”), a Delaware limited liability company. (Dkt. 5-1 ¶¶ 1, 9.) QuiO was created to develop, market, manufacture, and sell the SiOne Smart Injector medical device, which is a digital injector that can control the timing of injections and the injection process and monitor patient dosages. (Id. ¶ 10.) Dahmani is currently a citizen of Michigan and has a 9.855% ownership interest in QuiO. (Id. ¶ 1.)

Defendant SHL Medical is a Swiss corporation that is the successor in interest to, and assignee, of SHL Group, LTD (“SHL Group”). (Id. ¶ 3.) SHL Group is a limited liability company that was founded by SHL Medical as a single-purpose entity to serve as an instrumentality and vehicle for investment into QuiO; SHL Group was thus previously a member of QuiO. (Id. ¶ 6.) SHL Medical, however, was eventually substituted for SHL Group as a member of QuiO. (Id.) (Id. ¶ 2–3.)

1 In citations to the docket, page numbers are taken from the CM/ECF headers. 2 The Court takes the factual background from the well-pled allegations in the Complaint (Dkt. 6) and assumes the allegations to be true for the purposes of the instant motion. See, e.g., Anicich v. Home Depot U.S.A., Inc., 852 F.3d 643, 648 (7th Cir. 2017). Dahmani alleges that SHL Medical and SHL Group are part of a larger and complex group of related corporate entities (collectively, “SHL”) that have an “opaque” corporate structure. (Id.) SHL develops and manufactures drug delivery systems, and SHL Medical is SHL’s main operating company. (Id. ¶ 8.) SHL Medical is owned by Roger Samuelsson, a Swedish citizen. (Id. ¶ 3.)3 SHL Medical manufactures medical devices such as pen injectors, auto injectors, and inhaler systems. (Id.) The SiOne Smart Injector, which QuiO was meant to develop, was a potential digital substitute for the mechanical injectors that make up SHL’s main product line. (Id. ¶ 10.)

While QuiO was still in its infancy, SHL Medical approached QuiO with a funding offer through Dr. Ramin Raffei, a representative of SHL Medical. (Id. ¶¶ 15–19.) Dr. Raffei not only expressed interest in providing QuiO with funding, but also asked the QuiO founders, including Dahmani, whether they would be interested in entering into a partnership with SHL Medical. (Id. ¶¶ 15–20.) Through the proposed partnership, the QuiO founding members hoped to obtain financial, technical, manufacturing, and marketing support from SHL Medical so that they could develop the SiOne Smart Injector and bring it to market. (Id. ¶ 20.) Following SHL Medical and QuiO’s initial meeting, the QuiO founders and SHL Medical had several subsequent meetings, visited SHL Medical’s facilities, and eventually met with Samuelsson. (Id. ¶¶ 22–23.)

Dahmani alleges that, over the course of these meetings, which took place in Taiwan and Sweden, the “essentials” of QuiO and SHL’s deal were established. (Id. ¶¶ 22–24.) Specifically, Dahmani contends that SHL agreed to invest $15 million in QuiO (based on SHL’s estimate of the development cost of the SiOne hardware and associated software platform). (Id.) In exchange, SHL would obtain a 51% stake in QuiO, but there would be an equal split in representation on the Board of Managers between SHL and the QuiO founders. (Id.) Dahmani alleges that Samuelsson and his executives explicitly represented to the QuiO founders that SHL would provide monetary support, “engineering and technical support for product development, help with regulatory approval, and ultimately, contract with QuiO to manufacture the product.” (Id. ¶ 25.)

Eventually, QuiO and SHL memorialized the partnership in Chicago, Illinois on October 17, 2017, in a series of documents: (1) an Amended and Restated Operating Agreement; (2) a Subscription Agreement; (3) a Cooperation Agreement; and (4) a Service Agreement. (Id. ¶¶ 24, 26.) These documents reflected QuiO and SHL’s agreement that SHL would invest $15 million in QuiO, in the form of $10 million in cash and $5 million in “in-kind services” (such as engineering and development support). (Id. ¶ 28.) In return, SHL became a member of QuiO holding a 51% share of the LLC. (Id.) Subsequently, a Second Amended and Restated Operating Agreement (“Second Operating Agreement”) was executed, and it included a provision stating that SHL’s 51% interest in QuiO could not be diluted without SHL’s consent. (Id. ¶ 29.) Additionally, the Second Operating Agreement stated that “QuiO’s day-to-day affairs shall be conducted by a Board of Managers, consisting of two Managers appointed by the Founders and two managers appointed by SHL,” but that one of SHL’s managers would be the Chairman, who would have a tiebreaking vote. (Id.) After the parties formalized their agreement, SHL invested the $10 million in cash in QuiO, and QuiO began applying for patents, seeking regulatory approval, and developing the product. (Id. ¶ 31.)

3 The Court notes that Dahmani’s Complaint is somewhat unclear on whether Samuelsson owns all the SHL entities or only SHL Medical. That distinction, however, is ultimately immaterial to the Court’s resolution of the parties’ dispute. Soon thereafter, SHL and QuiO began to run into problems as QuiO felt that SHL’s manufacturing expertise and offerings were below the QuiO founders’ expectations and proved more expensive than anticipated. (Id. ¶¶ 32, 34–35.) One of QuiO’s complaints was that although SHL granted QuiO a $5 million credit for engineering and manufacturing services, SHL ended up charging QuiO for many services. (Id. ¶ 35.) QuiO was eventually required to pause the hardware development of the SiOne product, (id. ¶ 43), and the Board of Managers agreed that SHL should convert some of its $5 million in “in-kind services” to fund an internal engineering team. (Id.) Accordingly, SHL provided a cash infusion of $1.128 million to QuiO (which was taken from the initial $5 million capital contribution of “in-kind services”); the cash infusion was memorialized by Amendment No. 1 to the QuiO Subscription Agreement (“Amendment No. 1”). (Id. ¶ 44.)

Around the same time, EGT Group, a private equity firm, obtained a 20% minority stake in SHL Medical’s holding company. (Id. ¶ 46.) After the $1.128 million was exhausted and EQT had invested in SHL, SHL Medical refused to put any more money into QuiO, despite the QuiO founders’ repeated requests for additional cash infusions. (Id. ¶¶ 47, 49.) Further, SHL Medical refused to consider alternative sources of funding and to waive its antidilution rights.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Piper Aircraft Co. v. Reyno
454 U.S. 235 (Supreme Court, 1982)
Parfi Holding AB v. Mirror Image Internet, Inc.
817 A.2d 149 (Supreme Court of Delaware, 2002)
Douzinas v. American Bureau of Shipping, Inc.
888 A.2d 1146 (Court of Chancery of Delaware, 2006)
Deborah Jackson v. Payday Financial, LLC
764 F.3d 765 (Seventh Circuit, 2014)
Natasha Mueller v. Apple Leisure Corporation
880 F.3d 890 (Seventh Circuit, 2018)
GoldenTree Asset Management LP v. BNP Paribas S.A.
64 F. Supp. 3d 1179 (N.D. Illinois, 2014)
Pinkus v. Sirius XM Radio Inc.
255 F. Supp. 3d 747 (N.D. Illinois, 2017)
Deb v. Sirva, Inc.
832 F.3d 800 (Seventh Circuit, 2016)
Anicich v. Home Depot U.S.A., Inc.
852 F.3d 643 (Seventh Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Dahmani v. SHL Medical AG, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dahmani-v-shl-medical-ag-ilnd-2024.